{{Redirect-distinguish|Vanos|VANOS|VanossGaming}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 461101571
| IUPAC_name = 6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate
| image = Fluocinonide.png
<!--Clinical data-->
| tradename = Lidex
| Drugs.com = {{drugs.com|CONS|fluocinonide}}
| MedlinePlus = a601054
| pregnancy_category = C
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = topical
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = [[hepatic]]
| elimination_half-life =  
<!--Identifiers-->
| IUPHAR_ligand = 7078
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 356-12-7
| ATC_prefix = C05
| ATC_suffix = AA11
| ATC_supplemental =  {{ATC|D07|AC08}}
| PubChem = 9642
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01047
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9265
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2W4A77YPAN
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00325
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1501
<!--Chemical data-->
| C=26 | H=32 | F=2 | O=7
| molecular_weight = 494.525 g/mol
| smiles = O=C(OCC(=O)[C@]45OC(O[C@@H]5C[C@@H]2[C@@]4(C[C@H](O)[C@]3(F)[C@]/1(/C=C\C(=O)\C=C\1[C@@H](F)C[C@@H]23)C)C)(C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WJOHZNCJWYWUJD-IUGZLZTKSA-N
}}

'''Fluocinonide''' ('''Fluonex''', '''Lidex''', '''Lidex-E''', '''Lonide''', '''Lyderm''', and '''Vanos''')<ref>[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a601054.html MedlinePlus Drug Information: Fluocinonide Topical]</ref> is a potent [[glucocorticoid]] used [[topical]]ly as an [[anti-inflammatory]] agent for the treatment of [[skin disorder]]s such as [[eczema]] and [[seborrhoeic dermatitis]]. It relieves [[itch]]ing, redness, [[Xeroderma|dryness]], crusting, scaling, [[inflammation]], and discomfort.

The usual prescription concentration is 0.05% as a topical cream, ointment, solution, or gel.  The application area should normally not be covered after application. In certain cases, the physician may recommend the use of an [[occlusive dressing]] after application to increase the rate and depth of absorption.  The frequency of application depends on the condition being treated and the area affected, but most often it should be applied 2 to 4 times a day.<ref>{{cite web|title=Fluocinonide Topical|url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601054.html|work=MedlinePlus|publisher=US National Library of Medicine, NIH|accessdate=6 March 2014}}</ref>

Fluocinonide ranks as a "high-potency" (second-highest rank) topical [[corticosteroid]]. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects.{{medical citation needed|date=April 2013}}

Fluocinonide should not be used if infection is present. It should not be applied to the eyes or to sensitive areas such as the genitals or anus.{{medical citation needed|date=December 2013}}

A common potential adverse effect is skin atrophy (thinning of the skin). Systemic absorption of topical corticosteroids can produce reversible [[hypothalamic-pituitary-adrenal axis]] (HPA) suppression, manifestations of [[Cushing's syndrome]], [[hyperglycemia]], and [[glucosuria]] in some patients.

Fluocinonide should be used with caution when treating children, pregnant women, nursing mothers, and anyone using the medication for longer than two weeks.

Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs.<ref>Dog Allergies www.squidoo.com/dogallergy</ref> Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.<ref>{{cite journal |author=Zenoble RD, Kemppainen RJ .|title=Adrenocortical suppression by topically applied corticosteroids in healthy dogs |journal=J Am Vet Med Assoc |date=1987-09-15 |volume=191 |issue=6 |pages=685–8 |pmid=2824410}}</ref>

== See also ==
* [[Topical steroid]] relative strength groupings list

== References ==
{{Reflist|30em}}

{{Glucocorticoids}}
{{Vasoprotectives}}
{{Glucocorticoidics}}

[[Category:Acetate esters]]
[[Category:Acetonides]]
[[Category:Alcohols]]
[[Category:Corticosteroid cyclic ketals]]
[[Category:Corticosteroid esters]]
[[Category:Fluoroarenes]]
[[Category:Glucocorticoids]]
[[Category:Pregnanes]]
[[Category:Diketones]]